Context Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CNTX Nasdaq 2830 www.contexttherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Context Therapeutics Inc.

Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - Jun 11th, 2025 6:44 am
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - Jun 2nd, 2025 5:30 am
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - May 29th, 2025 5:30 am
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 12th, 2025 2:38 pm
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - May 7th, 2025 2:09 pm
Context Therapeutics Announces Chief Medical Officer Transition - May 5th, 2025 2:05 pm
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - Apr 30th, 2025 5:30 am
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - Apr 9th, 2025 5:30 am
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Apr 4th, 2025 6:51 am
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Apr 3rd, 2025 6:11 am
Context Therapeutics to Participate in Upcoming Investor Conferences - Apr 1st, 2025 5:30 am
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Mar 26th, 2025 2:02 pm
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Mar 22nd, 2025 7:40 am
Context Therapeutics Reports Full Year 2024 Operating and Financial Results - Mar 20th, 2025 2:22 pm
Context doses first subject in Phase I cancer trial of CTIM-76 - Jan 15th, 2025 9:29 am
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - Jan 14th, 2025 2:58 pm
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - Jan 13th, 2025 5:30 am
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - Nov 6th, 2024 2:06 pm
Context Therapeutics to Participate in Upcoming Investor Conferences in November - Oct 23rd, 2024 5:30 am
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - Oct 16th, 2024 5:30 am